Baystate Wealth Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Baystate Wealth Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$35.1K	Buy	364 +64	+21%	+$5.66K	﹤0.01%	442
2023 Q3	$26.5K	Hold	300	–	–	﹤0.01%	437
2023 Q2	$26K	Sell	300 -100	-25%	-$9.41K	﹤0.01%	426
2023 Q1	$38.9K	Hold	400	–	–	﹤0.01%	365
2022 Q4	$41K	Buy	+400	New	+$37.6K	﹤0.01%	356
2017 Q3	–	Sell	-10	Closed	-$1K	–	653
2017 Q2	$1K	Hold	10	–	–	﹤0.01%	552
2017 Q1	$1K	Buy	+10	New	+$890	﹤0.01%	516

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Baystate Wealth Management's BMRN Position: Q4 2023 in Review

Baystate Wealth Management increased its BioMarin Pharmaceuticals (BMRN) stake by 21% in Q4 2023, buying an estimated $5.66K and bringing the position to 364 shares worth $35.1K. The position accounts for ﹤0.01% of the portfolio, ranked #442.

Baystate Wealth Management first reported a position in BMRN in Q1 2017 and has held it in 7 quarters since. The position peaked at $41K in Q4 2022. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

Baystate Wealth Management held 364 shares of BioMarin Pharmaceuticals worth $35.1K as of Q4 2023.
Baystate Wealth Management bought 64 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $5.66K.
BioMarin Pharmaceuticals made up ﹤0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #442 holding.
Baystate Wealth Management first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 7 quarters since.
Baystate Wealth Management's BioMarin Pharmaceuticals position peaked at $41K in Q4 2022.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.